Farmas USA

Gráfico ARNA

Pajarracos y piratas varios, yo miraria esto....

http://www.seattlegenetics.com/pdf/SGEN_10K_2012.pdf

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company's lead program, ADCETRIS (brentuximab vedotin), received accelerated approval from the U.S. Food and Drug Administration in August 2011 and approval with conditions from Health Canada in February 2013 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional approval from the European Commission in October 2012. Seattle Genetics also has four other clinical-stage ADC programs: SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie (formerly Abbott), Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at www.seattlegenetics.com.

Sufrimiento.
El 18/04 es fecha ex date.
Yo saldria e intentaría entrar a posteriori. La estrategia sería aprovechar empuje que habrá para estar en el listing.Luego ya trailing stop y a correr

ARNA en Forbes. Vaya, vaya ...

http://www.forbes.com/sites/dividendchannel/2013/03/22/arena-pharmaceuticals-larger-than-sp-500-component-advanced-micro-devices/

edito: y otro articulo
http://seekingalpha.com/article/1296361-6-reasons-to-buy-arena-pharmaceuticals-right-now?source=email_rt_article_readmore

Aún no se el motivo de semejante descalabro. No veo noticias que lo justifiquen. De hecho hubo entrada de sangre azul. Crees que va a seguir bajando antes del ex date? QCOR

QCOR
Dinamica de mercado.Practicamente 1/2 está en corto y la ratio P/C tambien lo atestigua.
Me puedo equivocar, pero lo mas razonable seria salir y entrar al ex-date.
Llevamos un 41% desde Oct/12 y un 21% ytd. Se veia venir.

Consuelate: http://finviz.com/quote.ashx?t=ome&ty=c&ta=1&p=d

Pues estaré atento y si cojo valor saldré y si me acojono me quedo largo, no prometo nada :-). Vaya escalada de OME quien la hubiera pillado!!

1,2,3,4,5,6,7 y hasta 8 indicaciones en Fase III.
La Virgen! ... digo SGEN!
http://www.seattlegenetics.com/pipeline